C53.0
C53.0 — Malignant neoplasm of endocervix
Billable / specific codeICD-10-CM
C53.0 is a billable, specific ICD-10-CM code for malignant neoplasm of endocervix. It is valid for submission on a claim.
Risk adjustment
C53.0 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 22 Bladder, Colorectal, and Other Cancers0.363 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.
Medicare coverage
C53.0 is named in 69 Medicare coverage policies — 69 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A52370Billing and Coding: Bevacizumab and biosimilars
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52479Oral Anticancer Drugs - Policy Article
Related codes at this level
Codes that share C53. If C53.0 is not quite right, the correct code is usually one of these.
Questions about C53.0
- Is C53.0 a billable ICD-10-CM code?
- Yes. C53.0 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does C53.0 sit in the tabular list?
- Neoplasms (C00-D49), in the block Malignant neoplasms of female genital organs (C51-C58).